Cells differentiate when transcription factors bind accessible cisregulatory elements to establish specific gene expression programs. In differentiating embryonic stem cells, chromatin at lineage-restricted genes becomes sequentially accessible [1] [2] [3] [4] , probably by means of 'pioneer' transcription factor activity 5 , but tissues may use other strategies in vivo. Lateral inhibition is a pervasive process in which one cell forces a different identity on its neighbours 6 , and it is unclear how chromatin in equipotent progenitors undergoing lateral inhibition quickly enables distinct, transiently reversible cell fates. Here we report the chromatin and transcriptional underpinnings of differentiation in mouse small intestine crypts, where notch signalling mediates lateral inhibition to assign progenitor cells into absorptive or secretory lineages [7] [8] [9] . Transcript profiles in isolated LGR5 1 intestinal stem cells 10 and secretory and absorptive progenitors indicated that each cell population was distinct and the progenitors specified. Nevertheless, secretory and absorptive progenitors showed comparable levels of H3K4me2 and H3K27ac histone marks and DNase I hypersensitivity-signifying accessible, permissive chromatin-at most of the same cis-elements. Enhancers acting uniquely in progenitors were well demarcated in LGR5 1 intestinal stem cells, revealing early priming of chromatin for divergent transcriptional programs, and retained active marks well after lineages were specified. On this chromatin background, ATOH1, a secretory-specific transcription factor, controls lateral inhibition through delta-like notch ligand genes and also drives the expression of numerous secretory lineage genes. Depletion of ATOH1 from specified secretory cells converted them into functional enterocytes, indicating prolonged responsiveness of marked enhancers to the presence or absence of a key transcription factor. Thus, lateral inhibition and intestinal crypt lineage plasticity involve interaction of a lineage-restricted transcription factor with broadly permissive chromatin established in multipotent stem cells.
Intestinal crypts produce enterocyte and secretory (enteroendocrine, goblet, or Paneth) lineages after bipotential progenitors start to express ATOH1 and delta-like ligands, which activate Notch receptors on adjacent cells 8, 9 . Notch signalling silences Atoh1 expression in recipient cells and within 6 h ATOH1 1 cells adopt the secretory fate, whereas ATOH1 2 cells become enterocytes 9, 11, 12 (Extended Data Fig. 1a ); forced ATOH1 expression in mouse fetal intestines promotes secretory differentiation 13 . To investigate the chromatin basis for the deterministic activity of ATOH1 in lateral inhibition, we purified LGR5 1 intestinal stem cells from Lgr5 GFP-cre mouse crypts 10 (Extended Data Fig. 1b, c) . Exploiting a total absence of secretory cells in Atoh1 2/2 intestines 11, 12, 14 (Extended Data Fig. 1d , e), we also collected mature villus enterocytes ( Fig. 1f ) and their crypt progenitors (hereafter termed Ent-Pro, Fig. 1l d, e, j, k, p, q, By 4 days after Rbpj deletion, crypt cells cease replication (p), retain ATOH1 (j), and show weak Alcian blue staining (d); 2 days later, their goblet cell progeny occupy short villi (e, k, q). f, l, r, Atoh1 2/2 intestines lack secretory cells, carrying only enterocytes on villi (f) and replicating ATOH1 2 Ent-Pro in crypts (l, r). Scale bars, 50 mm. Duplicate samples were examined from three (Rbpj 2/2 and wild type (WT)) or seven (DBZ138 h and Atoh1 2/2 ) mice. progenitors (Sec-Pro cells), we separately depleted transcription factor RBPJ, which mediates notch responses 6, 7 , or disrupted notch signalling with the c-secretase inhibitor dibenzazepine (DBZ) 7, 15 . Both approaches induced replication arrest and an excess of all secretory cell types 12, 16 (Fig. 1e , q and Extended Data Figs 1f and 2). Four days after induced Rbpj deletion or 72 h after administration of DBZ, secretory cells appeared in all crypts, but not yet on villi ( Fig. 1d and Extended Data Fig. 2 ), revealing their origins in Sec-Pro cells. Accordingly, 1 day (Rbpj 2/2 ) or 1.5 days (DBZ) earlier, crypts uniformly showed high ATOH1 expression, ongoing cell replication, and negligible avidity for the goblet cell stain Alcian blue (Fig. 1b , c, h, i, n, o). Confirming that these ATOH1 1 cells are bona fide Sec-Pro cells, they robustly expressed known secretory genes 17 (for example, Neurog3, Gfi1, Spdef); moreover, Sec-Pro cells produced in different ways had similar expression profiles, distinct from characteristic transcripts enriched in other cell populations (Extended Data Fig. 3 and Supplementary Information Table 1 ). Although LGR5 1 intestinal stem cells, Sec-Pro and Ent-Pro cells share many transcripts, the divergent cell sources and expression profiles indicate that they represent discrete, specified crypt populations.
We used chromatin immunoprecipitation with deep sequencing (ChIP-seq) to first identify sites carrying H3K4me2, a robust mark of functional cis-element activity 18, 19 . As mammalian genes are controlled mainly through distant enhancers 20 , where tissue-restricted transcription factors bind DNA 21 , we concentrated on regions $2 kilobases (kb) upstream or $1 kb downstream of transcription start sites (TSSs). Highly concordant enhancer profiles in independent Ent-Pro replicates and in Sec-Pro obtained after genetic or chemical notch inhibition ( Fig. 2a, b and Extended Data Fig. 4 ) gave confidence in epigenome analysis of primary cells. As prevailing concepts predict, villus cells clustered farthest in aggregate analysis of H3K4me2-marked enhancers ( Fig. 2b ) because many enhancers were marked in mature enterocytes and goblet cells, but not in their progenitors (group 2 in Fig. 2a and Extended Data Fig. 5a ); these enhancers, delineated only in mature cells, showed significant transcription factor motif enrichment (Supplementary Information Table 2 ). To our surprise, not only were many enhancers prominently marked in progenitor cells, but H3K4me2 showed markedly similar distributions in Sec-Pro and Ent-Pro cells (group 1 in Fig. 2a and Extended Data Fig. 5b ). Marks were evident at these sites even in LGR5 1 intestinal stem cells, distinct from the group 2 profile, and aggregate analysis verified significant overlap of H3K4me2 enhancers among crypt populations ( Fig. 2b ). Sites that seemed superficially better marked in DBZ-derived Sec-Pro cells (group 1b) lacked transcription factor motif enrichment or other distinguishing features, and Sec-Pro-restricted genes were not enriched near these sites but distributed among enhancers marked in all three crypt populations ( Fig. 2a and Supplementary Information Tables 1 and 2). 
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As H3K4 is methylated at both poised and active cis-elements in embryonic stem (ES) cells 1 , the striking overlap in progenitor cell marks might reflect enhancer potential, distinct from enhancer activity; H3K27ac is thought to mark active enhancers specifically 22, 23 . Although many H3K4me2-marked enhancers lacked H3K27ac, global and local distributions of the latter were remarkably similar in Sec-Pro and Ent-Pro cells ( Fig. 2c, d ). DNase I hypersensitivity (DHS, an independent, direct measure of chromatin access) 24 was evident at most H3K4me2 sites and its distribution was also highly similar in Sec-Pro and Ent-Pro cells ( Fig. 2c, d) , distinct from DHS in other mouse tissues (Extended Data Fig. 5c ). Thus, thousands of enhancers for lineage-restricted genes show comparable histone activation and tissue-specific chromatin access in distinct, specified crypt progenitors, and most such sites carry H3K4me2 in intestinal stem cells. This early, indiscriminate delineation of enhancers offers a compelling explanation for crypt cell equipotency, a key feature of lateral inhibition, and reveals that intestinal lineage separation does not require differential chromatin priming in daughter cells and may instead rely principally on transcription factor activity.
ATOH1, a Sec-Pro-specific transcription factor, is an ideal candidate to confer selectivity (Extended Data Fig. 6a ). Flag ChIP-seq in Sec-Pro cells isolated from Atoh1 Flag mice 25 identified thousands of binding sites, most of them in highly conserved, distant enhancers carrying ATOH1 consensus motifs (Extended Data Figs 4b and 6b) and different from ATOH1 binding sites in cerebellar neurons 25 (Fig. 3a ). Intestinal and neuronal binding sites coincided with tissue-specific H3K4 methylation (Extended Data Fig. 6c ), attesting to the regulatory significance of this histone modification. Lateral inhibition requires Atoh1 repression in prospective Ent-Pro cells and ATOH1 activity in Sec-Pro cells 12, 14 , and the rapidity of ATOH1-induced lineage divergence 9 suggests that it may directly regulate genes driving lateral inhibition. Indeed, ATOH1 bound strongly to its own locus and those for notch ligands Dll1 and Dll4 (Fig. 3b ), but not Ent-Pro-specific loci such as Bcl2l15 (Extended Data Fig. 6d ). These findings support a cell-intrinsic, ATOH1-dependent mechanism for lateral inhibition and a simple, direct means for feed-forward maintenance of this bistable system 26 . ATOH1 also bound numerous loci implicated in secretory differentiation, including determinants of each sub-lineage, and the corresponding transcripts are low or absent in Atoh1 2/2 crypts ( Fig. 3b and Extended Data Fig. 6e , f). Strong, specific association of ATOH1 binding with Sec-Pro-restricted transcripts further indicates that ATOH1 activates secretory genes without binding or directly repressing enterocyte genes (Extended Data Fig. 6g ).
H3K4me2, H3K27ac and DHS signals at ATOH1-bound enhancers were, on average, equally strong in ATOH1 1 Sec-Pro and Ent-Pro cells, which categorically lack ATOH1 (Fig. 3c) . A few secretory loci showed modestly stronger features in Sec-Pro or goblet cells (Extended Data Fig. 5d ), but most profiles were similar in LGR5 1 intestinal stem cells and both progenitors (Fig. 3d ). Although in villus cells ATOH1 preferred sites marked only in goblet cells over those marked only in enterocytes, in crypts ATOH1 overwhelmingly favoured enhancers bearing H3K4me2 in all populations (Extended Data Fig. 7) . The pervasive demarcation of ATOH1-bound enhancers in Atoh1 2/2 Ent-Pro cells reveals that this transcription factor does not initiate or maintain chromatin access in crypt cells.
The extreme overlap of Sec-Pro and Ent-Pro enhancer profiles indicates persistence of cis-element marks after lineage specification. Intestinal lineages might therefore remain plastic beyond the period of lateral inhibition, and sustained chromatin access might explain why some differentiated crypt cells readily assume stem-cell properties 17, 27, 28 . Our findings indicate that chromatin in specified cells may stay responsive to the presence or absence of ATOH1. In Atoh1-null fetal intestines, an Atoh1 lacZ allele is expressed in enterocytes 14 , but this finding could represent a non-cell-autonomous effect of abortive lateral inhibition. We postulated prolonged, cell-autonomous ATOH1 control of lineage identity in specified cells.
To test this hypothesis, we suppressed notch in Atoh1 fl/fl ;villin-cre ER mice and waited past the period of widespread Sec-Pro differentiation 
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before administering tamoxifen to induce Atoh1 deletion; we also injected bromodeoxyuridine (BrdU) to monitor cell replication and turnover (Fig. 4a ). Crypts and villus bases in control Atoh1 fl/fl ;Cre 2 mice became filled with non-replicating goblet cells 3 days after notch inhibition, as expected ( Fig. 4b-d ), whereas ATOH1-depleted crypts showed substantial proliferation and many fewer Alcian-blue-avid cells ( Fig. 4e-g) . To demonstrate that this marked difference from control mice did not represent rescue by a few intestinal stem cells that might have eluded notch inhibition, but rather was due to secretory cell conversion to enterocytes, we followed cells for three additional days (Fig. 4a ). By this time notch-inhibited control Atoh1 fl/fl ;Cre 2 mice became moribund and had short villi containing only goblet cells that showed no BrdU labelling ( Fig. 4h-k) . Meanwhile, in the absence of notch suppression, BrdU tracer in wild-type or Atoh1 2/2 intestines had moved from crypts into villus tips (Extended Data Fig. 8a-d) , as expected.
Atoh1 fl/fl ;villin-cre ER mice remained fit and carried only alkalinephosphatase-expressing enterocytes on tall villi with abundant BrdU signal at the tips (Fig. 4l-o) . Thus, loss of ATOH1 results in cells that overcome secretory fate and replication arrest more than 2 days after notch inhibition to become Ent-Pro cells that proliferate and mature into functional enterocytes.
To verify cell-autonomous fate conversion, we used progesterone/ RU486-responsive Atoh1 cre-PR mice 29 . After RU486 injection, YFP signals in control Atoh1 cre-PR/1 ;Rosa26 YFP mice were confined to a few goblet and enteroendocrine cells, indicating weak but restricted Cre activity; four independent mice showed no labelling of enterocytes or cell stripes, crucially confirming absence of leaky Cre activity in intestinal stem cells or multipotent progenitors (Extended Data Fig. 8e, f) . We suppressed notch in Atoh1 cre-PR/fl ;Rosa26 YFP mice, then activated Cre selectively in ATOH1 1 secretory cells, thus deleting the floxed Atoh1 allele and simultaneously activating a fluorescent lineage tracer (Fig. 4p ). Four days later, stripes of YFP 1 cells emanated from crypts and 95 6 4.1% (s.d.) of YFP 1 ATOH1-depleted cells (n 5 1,200 cells; 4 mice) in these ribbons lacked the goblet cell marker TFF3 but expressed alkaline phosphatase (Fig. 4q-s and Extended Data Fig. 8g ), confirming bona fide conversion of secretory cells to enterocytes. Thus, specified secretory cells are not irrevocably committed and their switched identity upon ATOH1 withdrawal mirrors the broadly permissive chromatin in crypt cells.
Mathematical modelling indicates that bifurcating valleys in Waddington's epigenetic landscape best represent reversible nodes, a hallmark of lateral inhibition 26 . The broad priming of intestinal stem cell and progenitor cell enhancers offers a satisfying explanation for this property in intestinal crypts and accounts for ATOH1 activity in both lateral inhibition and secretory differentiation. ATOH1 reinforces its own expression and directly regulates Dll1 and Dll4, thus enabling notch-dependent Atoh1 repression in neighbouring cells; its subsequent activity at primed cis-elements triggers numerous secretory genes. Sustained enhancer priming allows ATOH1 activity or its absence, which respectively promotes or represses secretory differentiation 13 , to affect the fate of specified cells, and DNA methylation also barely changes as intestinal stem cells differentiate 30 . True lineage commitment thus occurs late, if ever, in the intestinal epithelium. Indeed, various stimuli revert differentiated cells into intestinal stem cells with surprising ease 17, 27, 28 , indicating that the environment, and not some cell-intrinsic feature, determines crypt cell potential. Broadly delineated enhancers probably underlie this remarkable plasticity.
METHODS SUMMARY
Mouse strains were received as gifts or purchased from The Jackson Laboratory, as referenced in Extended Data Table 1 . We characterized epigenomes in cells isolated from the first half of small intestines isolated from 2-6-month-old male and female C57BL/6 mice. Detailed protocols to isolate crypt and villus cell populations are described in the Methods. Chromatin sheared by sonication was precipitated with H3K4me2 (Millipore 07-030), H3K27ac (Abcam ab4729), or Flag (Sigma F3165) antibodies; precipitated DNA was amplified using ThruPLEX-FD kits (Rubicon Genomics). For DNase I hypersensitive (DHS)-seq, nuclei were treated with 25 U, 40 U or 50 U DNase I (Roche), followed by procedures described in the Methods. ChIP and DHS libraries were sequenced using Hi-seq 2000 (Illumina).
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Animals and drug administration. Mouse strains were purchased from The Jackson Laboratory or received as gifts and are referenced in Extended Data Table 1 . Mice, maintained under specific pathogen-free conditions, were handled in accordance with protocols approved and monitored by the Dana-Farber Cancer Institute Animal Care and Use Committee. Male and female C57BL/6 mice were used between 2 and 6 months of age, without randomization or blinding. Dibenzazepine (DBZ, Syncom) was suspended in 0.5% (w/v) hydroxypropylmethyl-cellulose (Methocel E4M, Dow Chemicals) and 0.1% (w/v) Tween 80 (Bio-Rad) in water and 100 mmol kg 21 was administered by intraperitoneal injection. We activated Cre-ER recombinase by intraperitoneal injection of 1 mg tamoxifen (Invitrogen) for 5 days or one dose of 4 mg tamoxifen. Cre-PR recombinase was induced by two intraperitoneal injections of 2 mg RU486 (Sigma) approximately 8 h apart. BrdU (B-D Biosciences, 50 mg kg) was injected intraperitoneally and mice were killed 1 h or 3 days later. Cell isolation. Epigenomes were characterized in cells isolated from the first half of the small intestine.
LGR5 1 intestinal stem cells: intestinal villi in Lgr5 GFP-IRES-cre mice 10 were scraped away using glass slides, crypt epithelium was collected by shaking in 5 mM EDTA for 50 min at 4 uC, and single-cell suspensions prepared by digestion in 43 TrypLE (Invitrogen) for 50 min at 37 uC. GFP hi (LGR5 1 ) cells were sorted using a MoFlo instrument (Beckman Coulter). Sec-Pro and goblet cells: villi were scraped from intestines of wild-type mice 38 h after intraperitoneal injection of DBZ (Syncom, 100 mmol kg 21 intraperitoneally) and crypt cells isolated by shaking residual, crypt-enriched tissue in 5 mM EDTA for 50 min at 4 uC. Rbpj fl/fl ; villin-cre ER mice were injected with twice daily intraperitoneal doses of 2 mg tamoxifen, followed by isolation of crypt Sec-Pro as above on the third day, or with 5 daily doses of 1 mg tamoxifen, followed by isolation of villus goblet cells on the tenth day. The latter were collected by shaking intestines gently in 5 mM EDTA for 30 min at 4 uC, followed by passage through 70 mm filters to eliminate contaminating crypts. Ent-Pro and enterocytes: crypt epithelial cells and mature enterocytes were collected from Atoh1 fl/fl ;villin-cre ER intestines 14 days after tamoxifen treatment, as described for other mice. peaks from all study samples were merged to create a union set. Read densities (in reads per 1 million tags (RPM) within fixed, 200-bp bins) were calculated by normalizing counts in each peak region in the union set based on sample sequencing depth. Meta-analyses around ATOH1 binding sites were performed in the Cistrome pipeline 35 . Genomic wiggle traces were normalized for sample sequence depth. Similarities among H3K4me2-marked enhancers in different cell types were determined by hierarchal clustering using Spearman's rank correlation. Expression analyses and correlation with Atoh1 occupancy. RNA was extracted from LGR5 1 intestinal stem cells, Sec-Pro, Ent-Pro, goblet cells and enterocytes with Trizol (Invitrogen) and RNeasy Mini Kits (Qiagen), processed, and hybridized to Mouse Genome 430A 2.0 microarrays (Affymetrix). Data quality was verified using Affy QC Report in R bio-conductor. mRNA profiles were analysed by RMA to normalize expression indices 36 , and differential expression across cell types was identified using LIMMA 37 by F test with P # 0.002. Values in the expression heat map (Extended Data Fig. 3) were normalized by magnitude normalization and celltype specificity was determined by k-means clustering of differentially expressed genes. ATOH1 binding at enhancers was used as a function to determine if ATOH1 activates Sec-Pro-specific genes. Each ATOH1 enhancer ($2 kb upstream or #1 kb downstream from a TSS) was assigned to a nearby gene (TSS #20 kb from an ATOH1 summit). After normalization of tags for sequence depth and peak width, the sum of tag densities for each gene was used to measure its correlation with differential expression. Histology, immunohistochemistry and immunofluorescence. Mouse jejuni (middle third of the small intestine) were fixed overnight in 4% paraformaldehyde at 4 uC and embedded in paraffin. Rehydrated 5 mm sections were stained with Alcian blue (Sigma) and nuclear fast red (Sigma). For immunohistochemistry, antigens were retrieved in 10 mM sodium citrate buffer (pH 6). Tissue sections were permeabilized with 0.5% Triton X-100 (Sigma), blocked with 5% fetal calf serum (Gibco), incubated with Ki67 (Vector Laboratories clone MM1, 1:1,000), BrdU (AbD Serotec, 1:300), or ATOH1 (gift from J. Johnson, 1:500) antibodies, and washed in phosphate-buffered saline. Sections were incubated with biotinconjugated anti-mouse, rat or rabbit IgG (Vector Laboratories, 1:300) and colours developed with Vectastain avidin-biotin complex (Vector) and diaminobenzidine substrate (Sigma). ATOH1 immunostaining was enhanced with the Tyramide Signal Application kit (Perkin-Elmer). For immunofluorescence, tissues embedded in Optimal Cutting Temperature compound (Sakura) were sectioned and incubated with chromogranin A (ImmunoStar, 1:200), mucin2 (Santa Cruz, 1:200), or TFF3 (gift from D. Podolsky, 1:500) antibodies. After washings, samples were incubated with Alexa Fluor 594-conjugated anti-rabbit IgG (Invitrogen). In the lineage conversion experiments in Atoh1 cre-PR/fl ;Rosa26 YFP mice ( Fig. 4p-s) , tissue sections were stained sequentially with TFF3 antibody and alkaline phosphatase substrate.
